Northern Exposure PR

We are the leading public relations company serving the life science, pharmaceutical and technology industries.

Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.

Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management

Northern Exposure Public Relations  is uniquely skilled in assisting clients in all public relations requirements

Meet Our Team


Richard Kerns

Richard Kerns

Managing Director

Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.

Edward Dutton

Edward Dutton

Vice President

Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.

Sarah Houlton

Sarah Houlton

Technical Consultant in Residence

Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.

Our Services

NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:

Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more. 

Contact us today to find out how we can assist you

Our Clients

Client News

05/09/2019 Catalent to Open New Clinical Supply Facility in San Diego

12/09/2019 Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board

17/09/2019 SGS Appoints Steven Thys as Director of Global Clinical Operations

24/09/2019 Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

03/10/2019 Catalent Appoints Dr. Guy Dewil as General Manager of its Clinical Supply Facility in Schorndorf, Germany

06/11/2019 Catalent’s Chair & Chief Executive Officer, John Chiminski, Receives First Ever ‘Lifetime Achievement’ Award at CPhI Worldwide

14/11/2019 Cambrex Wins Third API Development Award at CPhI Worldwide

19/11/2019 Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation

21/11/2019 Catalent to Supply BeiGene’s BTK Inhibitor BRUKINSA™ (zanubrutinib)

03/12/2019 Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

04/12/2019 Cambrex Announces Completion of Acquisition by the Permira Funds

10/12/2019 Catalent Partners with Bridge Therapeutics on Formulation, Development and Production of New Opioid Addiction Treatment

12/12/2019 Catalent Launches New CTSuccess™ Service to Guide Sponsors to Smarter Clinical Trial Supply Planning

06/01/2020 Cambrex Announces Management Changes and Board Appointments

07/01/2020 Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy

14/01/2020 Catalent Launches FlexDirect™ Direct-to-Patient Clinical Supply Services

16/01/2020 Catalent Further Strengthens Biologics Business with Key Senior Appointments

29/01/2020 Catalent Appoints Ricci Whitlow to Lead Clinical Supply Services Business

03/02/2020 Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform

10/02/2020 Vectura announces the appointment of Sharon Johnson, Executive Vice President for Delivery Management

11/02/2020 Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors

12/02/2020 Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery

25/02/2020 Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-Rated Generic Version of ProAir® HFA

27/02/2020 Catalent Announces Supplying Blueprint Medicines’ Precision Therapy AYVAKIT™ (avapritinib)

09/03/2020 Vectura appoints Mark Bridgewater as Chief Commercial Officer

17/03/2020 Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

Upcoming Events

NEPR will be attending the following events:

CPhI North America

April 30–May 2, 2019

Chicago, IL

Healthcare Estates

October 8 – 9, 2019

Manchester, UK

CPhI Worldwide

November 5 – 7, 2019

Frankfurt, Germany